Prothena Corporation (NASDAQ:PRTA) is an early-stage, biotechnology company developing targeted antibody-based therapies for patients with AL amyloidosis, Parkinson's disease, and inflammatory / oncology conditions. Prothena's business is derived from Elan Pharmaceuticals (developers of now Biogen's successful Tysabri), and consists of a substantial portion of Elan's former drug discovery business platform, as well as its management team. PRTA's shares began trading on the NASDAQ on December 21, 2012 at $8/share. Since then, the shares have risen to as high as $49/share on the initial release of positive Phase 1 data for lead candidate NEOD001 in patients with amyloidosis in mid-March. Recently, the shares have fallen dramatically to approximately $21/share on the release of additional, patient level data of...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|